Drug Development · global
Directly Targeting Cyclin D1: Circle Raises $92.5 Million to Advance Breast Cancer Drug
Oral drug candidate CID-165 aims to block a protein interaction needed for cancer cell proliferation and is expected to enter clinical development in the first quarter of 2027. The new funding will support early trials, but evidence of efficacy currently comes only from preclinical models.
One approach to stopping cancer cells from dividing, beyond inhibiting the enzymes that drive the cell cycle, is to block contact between key proteins involved. Circle Pharma is pursuing this approach with its breast cancer drug candidate CID-165. On September 16, 2026, the company announced the completion of a $92.5 million Series E financing round, preparing to move the program, which remains at the preclinical stage, into human studies.
The oversubscribed round was led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly. Wilson Sonsini, the law firm that assisted with the transaction, also confirmed the financing amount and investor lineup the following day. The funds will support early clinical development of CID-165 for estrogen receptor-positive (ER-positive) breast cancer and advance other macrocyclic drugs targeting cyclins.
CID-165 is an oral macrocycle that targets the RxL binding site of cyclin D1. According to the company, the drug is designed to selectively block the interaction between cyclin D1 and the retinoblastoma protein (Rb), allowing Rb to retain its function of suppressing cell proliferation. The strategy centers on interfering with contact between proteins to limit tumor growth.
The company said CID-165 demonstrated antitumor activity both alone and in combination with other therapies in preclinical cancer models driven by cyclin D1. Combination studies included CDK4/6 inhibitors, selective CDK4 inhibitors and endocrine therapy. These results provide a rationale for exploring combination treatment, but they do not yet establish how much additional benefit adding CID-165 could bring to patients.
According to the announcement, CID-165 is expected to enter clinical development in the first quarter of 2027, which remains the company's planned timeline. The announcement did not provide the number of models, magnitude of effects or toxicology data needed for a full assessment, nor did it report human safety or efficacy results. Whether the drug can achieve effective exposure in humans, and how well it will be tolerated in combination with other drugs, remain questions for trials to answer.
The funding gives the concept of directly interfering with cyclin D1 an opportunity to move from experimental models to clinical testing. The next substantive milestone will be early human studies: establishing usable doses and safety, and looking for signals of antitumor activity, to enable further assessment of this mechanism's role in treating ER-positive breast cancer.